Foundayo approval a welcome addition to GLP-1 treatment options 18 November 2026 Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a new oral GLP-1 receptor agonist for the management of type 2 diabetes and chronic weight management in eligible adults. Foundayo was entered on the Australian Register of Therapeutic Goods on 16 November 2026. The new medicine provides a once-daily oral treatment option, offering an alternative for eligible people who may prefer a tablet to a self-administered injection. It can be taken without specific food or water restrictions, providing additional flexibility for people who use it. Diabetes Australia Group CEO Justine Cain welcomed the approval, saying additional treatment options were positive for people living with type 2 diabetes and people requiring medical treatment for obesity, while noting that regulatory approval did not necessarily guarantee affordable or equitable access. “GLP-1 medicines have significantly expanded treatment options for many people living with type 2 diabetes and obesity, and it is encouraging to see new formulations becoming available,” Ms Cain said. “Importantly, regulatory approval does not automatically mean that a medicine will be affordable or equitably accessible to everyone who could benefit. “As new treatments emerge, we need to ensure that decisions about access and affordability are guided by strong clinical evidence and health need, rather than a person’s capacity to pay. “For some people, the cost of these medicines remains a significant barrier. We need to continue looking at evidence-based approaches to subsidised access so that people who are clinically most likely to benefit are not excluded because they cannot afford treatment. “Innovation is important, but so is equitable access. A treatment can only improve health outcomes if the people who stand to benefit can actually access it.” Ms Cain said the introduction of new GLP-1 medicines also highlighted the importance of ensuring medicines were provided as part of comprehensive, person-centred healthcare. “As access to GLP-1 medicines expands, we also need to ensure people receive appropriate clinical care and support, including nutrition, physical activity, psychological support where needed, and long-term follow-up,” Ms Cain said. “It is equally important to ensure these treatments are prescribed appropriately, used safely and deliver the greatest possible health benefit.” TGA approval and registration on the Australian Register of Therapeutic Goods is distinct from PBS subsidy. Foundayo’s registration by the TGA does not mean that the medicine will be subsidised through the Pharmaceutical Benefits Scheme. Diabetes Australia encourages people interested in GLP-1 medicines to speak with their GP, endocrinologist, pharmacist or other appropriately qualified healthcare professional about the potential benefits, risks and suitability of treatment for their individual circumstances.
Blog 17 November 2026 Create a festive spread for all to enjoy Our favorite festive foods for a joyful Christmas Continue Reading
Blog 11 November 2026 6 simple food swaps for a feel-good festive season From the BBQ to the dessert table, here are six simple swaps to bring fresh flavour to your festive favourites, plus recipe ideas to get you started. Continue Reading
Media releases 6 November 2026 Diabetes Australia welcomes new oral GLP-1 treatment option for Australians Diabetes Australia welcomes the Therapeutic Goods Administration’s (TGA) recent approval of a new oral formulation of Wegovy (semaglutide) as a step forward in the treatment of obesity and related chronic conditions. Continue Reading